Category Archives: Patent

Pharma PSUs Are Not Ready To Die!

By Murali Neelakantan, BloombergQuintOpinion | February 7, 2017 The government’s decision to explore the strategic sale of Indian Drugs and Pharmaceuticals Ltd. and Bengal Chemicals – even as questions were asked of the move last week by parliamentarians including those from the BJP … Continue reading

Posted in Generics, Patent, Pricing, Uncategorized | Leave a comment

Demonstrations held at Roche & pharma associations in South Africa, Malaysia, UK, France, Zambia, Brazil, US

Source: TAC Tuesday, 7th February 2017 –* Swiss multinational company Roche faced global condemnation today from women living with cancer, families of people with cancer, activists, scientists, researchers and health professionals from across the world. They highlighted the immoral and unconscionable tactics employed by … Continue reading

Posted in Cancer, Evergreening, Patent, Uncategorized | Leave a comment

Health grps ask Centre to include ‘delamanid’ for TB control

Published: Business Standard| Source: PTI , January 28, 2017 Health groups have asked the Centre to incorporate the life-saving anti-TB drug ‘delamanid’ into its Revised National Tuberculosis Control Programme. In a letter to the Health Ministry, the groups have asked … Continue reading

Posted in Patent, Tuberculosis (TB), Uncategorized | Tagged , , | Leave a comment

President-Elect Trump Says the TPP is Dead, but What Now for IP?

By Sirena Rubinoff, IPWatchdog |December 15, 2016 President-Elect Donald Trump has announced that he will withdraw the United States from the Trans-Pacific Partnership (TPP) agreement on his first day in office. So ends more than five years of often heated negotiations … Continue reading

Posted in Data Exclusivity, Patent, Patent Term Extension, TPP, Uncategorized | Leave a comment

Patent denied, price of prostate cancer drug may go down

The Indian Patent Office recently denied a patent for the drug Xtandi (Enzalutamide) by Japanese firm Astellas Pharma used in  treatment of prostate cancer. This decision comes in the light of the pre-grant opposition filed by pharma companies BDR Pharma, drug … Continue reading

Posted in Bayh Dole Act, March in rights, Patent, Patent Opposition, Sec 3 (d), Uncategorized | Tagged | Leave a comment

Just the Medicine

How the next president can lower drug prices with the stroke of a pen. By Alicia Mundy, Washington Monthly | Nov/Dec 2016 It’s hard to watch television or read a newspaper these days without seeing stories about outrageous prescription drug … Continue reading

Posted in Bayh Dole Act, Drug prices, Patent, R&D, Uncategorized | Leave a comment

RCEP patent clauses lack compassion says Public Health Association

Public Health Association media release 21 October 2016 The Public Health Association of New Zealand (PHA) is calling on New Zealand Government negotiators to oppose clauses in the Regional Comprehensive Economic Partnership (RCEP), currently being negotiated, that would increase the … Continue reading

Posted in Data Exclusivity, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment